Medical Devices Saudi Arabia

Saudi Arabia Pharmacogenomic Testing for Psychiatry Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Saudi Arabia Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $8.5 Mn Placeholder estimate
Estimate 2025 $9.5 Mn 2% of the global market
Projected 2034 $25.4 Mn 168.5% Adds $16.0 Mn over 9 forecast years
CAGR 2025–2034 11.6% Faster than 63% of 186 Medical Devices markets here
Key players 5
  • Saudi Arabia is 1.96% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $9.5 Mn.
  • Fastest growing: Saudi Arabia (this report) at 11.6% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$16.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing for Psychiatry Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $8.5 Mn — —
2025 (base) $9.5 Mn +$1.0 Mn —
2026 (forecast) $10.6 Mn +$1.1 Mn +11.6%
2027 (forecast) $11.8 Mn +$1.2 Mn +24.5%
2028 (forecast) $13.2 Mn +$1.4 Mn +39%
2029 (forecast) $14.7 Mn +$1.5 Mn +55.1%
2030 (forecast) $16.4 Mn +$1.7 Mn +73.1%
2031 (forecast) $18.3 Mn +$1.9 Mn +93.2%
2032 (forecast) $20.4 Mn +$2.1 Mn +115.6%
2033 (forecast) $22.8 Mn +$2.4 Mn +140.6%
2034 (forecast) $25.4 Mn +$2.6 Mn +168.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Saudi Arabia Pharmacogenomic Testing for Psychiatry Market Analysis at a glance
Market size, 2025$9.5 Mn placeholder estimate
Forecast, 2034$25.4 Mn placeholder estimate
Growth (CAGR), 2025–203411.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all)
Regulator in Saudi ArabiaSFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Saudi Arabia Pharmacogenomic Testing for Psychiatry Market Analysis Executive Summary

Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.

Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).

Bar chart: Saudi Arabia Pharmacogenomic Testing for Psychiatry market size, 2024–2034, placeholder estimates. $8.5 Mn in 2024, $9.5 Mn in 2025 and $25.4 Mn in 2034, 11.6% CAGR.
Saudi Arabia Pharmacogenomic Testing for Psychiatry market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Saudi Arabia Pharmacogenomic Testing for Psychiatry Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.

Competitive Landscape for Pharmacogenomic Testing for Psychiatry Market in Saudi Arabia

The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing for Psychiatry Market in Saudi Arabia

Pharmacogenomic Testing for Psychiatry in Saudi Arabia: rules, payment and health figures

Medical devices need marketing authorisation from the Saudi Food and Drug Authority (SFDA).⁠[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).⁠[2] Suicide rate: 2.2 per 100,000 people in 2023, the latest WHO figure for Saudi Arabia.⁠[3]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Council of Health Insurance. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Saudi Arabia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing for Psychiatry in context

Saudi Arabia compared

  • Suicide rate: 2.2 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 5th highest of the 10 countries we cover in Middle East.[1]
  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 10 countries we cover in Middle East.[2]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 10 countries we cover in Middle East.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing for Psychiatry market in Saudi Arabia?
Placeholder estimate: about $9.5 Mn in 2025, rising to about $25.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing for Psychiatry market in Saudi Arabia growing?
Placeholder estimate: about 11.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing for Psychiatry market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Depression, Anxiety, ADHD, Bipolar Disorder) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing for Psychiatry market?
Key players include Myriad Genetics, Inc., Genomind, OneOme, Tempus and Thermo Fisher Scientific Inc..
What is driving the Pharmacogenomic Testing for Psychiatry market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Who regulates Pharmacogenomic Testing for Psychiatry in Saudi Arabia?
Medical devices need marketing authorisation from the Saudi Food and Drug Authority (SFDA). Source: Saudi Food and Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Saudi Arabia?
Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI). Source: Council of Health Insurance. Checked 14 Nov 2026.
What does WHO report for Saudi Arabia?
Suicide rate: 2.2 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 21 Nov 2026.
How many people in Saudi Arabia are 65 or older?
3.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
How much research is published on Pharmacogenomic Testing for Psychiatry?
PubMed lists 6 papers on Pharmacogenomic Testing for Psychiatry added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Saudi Arabia

See all

Related on mental health and genomics

See the topic